<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02044653</url>
  </required_header>
  <id_info>
    <org_study_id>GX-E2_P2</org_study_id>
    <nct_id>NCT02044653</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)</brief_title>
  <official_title>Phase II Clinical Trial to Explore the Optimal Fixed Starting Dose &amp; Dosing Interval and to Evaluate the Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease and Receiving Hemodialysis (HD) / Peritoneal Dialysis (PD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of study is&#xD;
&#xD;
        -  Part A : To explore the optimal fixed starting dose and dosing interval of GX-E2&#xD;
&#xD;
        -  Part B : To evaluate the proof of concept (POC) of GX-E2&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objective of study is to evaluate:&#xD;
&#xD;
        -  change of red blood cell indices in anemic patients with chronic kidney disease&#xD;
           receiving hemodialysis/peritoneal dialysis when administering GX-E2&#xD;
           intravenously/subcutaneously&#xD;
&#xD;
        -  change of reticulocyte indices in anemic patients with chronic kidney disease receiving&#xD;
           hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously&#xD;
&#xD;
        -  safety of GX-E2 when administering intravenously/subcutaneously&#xD;
&#xD;
        -  incidence of blood transfusion in anemic patients with chronic kidney disease receiving&#xD;
           hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously&#xD;
&#xD;
        -  Immunogenicity in anemic patients with chronic kidney disease receiving&#xD;
           hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2014</start_date>
  <completion_date type="Actual">April 20, 2017</completion_date>
  <primary_completion_date type="Actual">April 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>average change of Hemoglobin level</measure>
    <time_frame>6 weeks (Part A) &amp; 14 weeks (Part B)</time_frame>
    <description>change from baseline in Hemoglobin level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of red blood cell indices</measure>
    <time_frame>6 weeks (Part A) &amp; 14 weeks (Part B)</time_frame>
    <description>change from baseline in red blood cell indices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of reticulocyte indices</measure>
    <time_frame>6 weeks (Part A) &amp; 14 weeks (Part B)</time_frame>
    <description>change from baseline in reticulocyte indices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence, degree, outcome of adverse event</measure>
    <time_frame>6 weeks (Part A) &amp; 14 weeks (Part B)</time_frame>
    <description>Incidence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence, frequency, amount of blood transfusion</measure>
    <time_frame>6 weeks (Part A) &amp; 14 weeks (Part B)</time_frame>
    <description>Incidence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogenicity: ratio of neutralizing antibody &amp; binding antibody in subjects</measure>
    <time_frame>6 weeks (Part A) &amp; 14 weeks (Part B)</time_frame>
    <description>comparison from pre-treatment to post-treatment</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>Anemia</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Group A (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 3ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 3ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 5ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 8ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I (Part B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MIRCERA : Subcutaneously injection every 2 weeks (Q2W) at dose 0.6ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group J (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Intravenously injection every week (Q1W) at dose 5ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Intravenously injection every week (Q1W) at dose 8ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group L (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Intravenously injection every 2 weeks (Q2W) at dose 8ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M (Part B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NESP : Intravenously injection every week (Q1W) at dose 30ug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-E2</intervention_name>
    <description>Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg</description>
    <arm_group_label>Group A (Part A)</arm_group_label>
    <arm_group_label>Group B (Part A)</arm_group_label>
    <arm_group_label>Group C (Part A)</arm_group_label>
    <arm_group_label>Group D (Part A)</arm_group_label>
    <arm_group_label>Group E (Part A)</arm_group_label>
    <arm_group_label>Group F (Part A)</arm_group_label>
    <other_name>GC1113</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-E2</intervention_name>
    <description>Each Group of Peritoneal dialysis patients (n=24) will be administered GX-E2 5ug/kg to 8ug/kg</description>
    <arm_group_label>Group G (Part B)</arm_group_label>
    <arm_group_label>Group H (Part B)</arm_group_label>
    <other_name>GC1113</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-E2</intervention_name>
    <description>Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg</description>
    <arm_group_label>Group J (Part B)</arm_group_label>
    <arm_group_label>Group K (Part B)</arm_group_label>
    <arm_group_label>Group L (Part B)</arm_group_label>
    <other_name>GC1113</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NESP</intervention_name>
    <description>Each Group of Hemodialysis (n=30) will be administered NESP 30ug</description>
    <arm_group_label>Group M (Part B)</arm_group_label>
    <other_name>Aranesp</other_name>
    <other_name>Darbepoetin alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIRCERA</intervention_name>
    <description>Each Group of Peritoneal dialysis (n=24) will be administered MIRCERA 0.6ug/kg</description>
    <arm_group_label>Group I (Part B)</arm_group_label>
    <other_name>Methoxy Polyethylene glycol-epoetin beta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  ≥18 yr of age&#xD;
&#xD;
          -  Chronic Kidney diseases with hemodialysis, peritoneal dialysis with Kt/V ≥ 1.2&#xD;
             (hemodialysis) or Kt/V ≥ 1.7 (peritoneal dialysis) within a year&#xD;
&#xD;
          -  Adequate transferrin saturation (≥20%), serum ferritin (≥100ug/L)&#xD;
&#xD;
          -  Should have received Vitamine B12 ≥ 3 months before the first dose of study agent&#xD;
&#xD;
          -  Should have received Folate ≥3 months before the first dose of study agent&#xD;
&#xD;
          -  No erythropoietin (EPO) therapy within 2 months before the planned first dose of GX-E2&#xD;
             and Hb&lt;10g/dL or No EPO therapy within a month (peritoneal dialysis) or 2 weeks&#xD;
             (hemodialysis) before the planned first dose of GX-E2 and Hb&lt;10g/dL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refractory to erythropoiesis stimulating agent (ESA) treatment&#xD;
&#xD;
          -  History of blood transfusion within 3 months&#xD;
&#xD;
          -  Donation or loss of blood for more than 400 milliliters (mL) within 8 weeks&#xD;
&#xD;
          -  History of a known or suspected hypersensitivity, shock, or past history to the&#xD;
             investigational drug or to similar ESA drugs&#xD;
&#xD;
          -  Acute or chronic organ seizure disorder (including asthma and chronic obstructive&#xD;
             pulmonary disease) which may be clinically deteriorated by the drug administration&#xD;
&#xD;
          -  Active infection or history of infection that required intravenous injection of&#xD;
             antibiotics in the last two months&#xD;
&#xD;
          -  Grand Mal epilepsy&#xD;
&#xD;
          -  Major surgery within 3 months other than access surgery&#xD;
&#xD;
          -  Malignant tumor within 5 years other than successfully treated skin cancer that is not&#xD;
             melanoma&#xD;
&#xD;
          -  Ischemic stroke within 3 years&#xD;
&#xD;
          -  Chest x-ray findings determined that they cannot participate in the study for&#xD;
             clinically abnormal findings by the baseline chest x-ray findings or previously taken&#xD;
             chest x-ray findings&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Congestive heart failure more severe than NYHA functional class III; unstable Coronary&#xD;
             artery disease (CAD); myocardial infraction within 3 months&#xD;
&#xD;
          -  Uncontrolled arrhythmia&#xD;
&#xD;
          -  High risk of thrombosis and embolism&#xD;
&#xD;
          -  Systemic blood diseases (e.g. Pure red cell anemia, sickle cell anemia,&#xD;
             myelodysplastic syndromes, hematologic malignancy, myeloma, hemolytic anemia)&#xD;
&#xD;
          -  Absolute neutrophil count below 1,500 per microliter (uL) within screening periods&#xD;
&#xD;
          -  Platelet count less than 5e10 per liter (L) within screening periods&#xD;
&#xD;
          -  Hyperparathyrodism / hypothyrodism&#xD;
&#xD;
          -  Splenomegaly caused by anemia or severe splenomegaly (&gt;20cm)&#xD;
&#xD;
          -  Blood aspartate aminotransferase/alanine aminotransferase (ALT/AST) concentration&#xD;
             exceeds three times Upper Normal Limit of Normal (UNL)&#xD;
&#xD;
          -  Blood total bilirubin concentration exceeds 1.5 times Upper Normal Limit of Normal&#xD;
             (UNL)&#xD;
&#xD;
          -  Blood albumin concentration below 3g per deciliter (dl)&#xD;
&#xD;
          -  History of drug or alcohol abuse in the 6 months prior to the screening&#xD;
&#xD;
          -  History of psychotropic or narcotic analgesic drugs dependence within 6 months prior&#xD;
             to the screening&#xD;
&#xD;
          -  Mental disorder or other central nervous system disorder determined that the study&#xD;
             evaluation cannot be conducted&#xD;
&#xD;
          -  Lack of understanding of the study and cooperation (one with no intention to give&#xD;
             efforts to perform each evaluation visit and extend previously planned elective&#xD;
             surgery)&#xD;
&#xD;
          -  Female subjects with childbearing potential who are pregnant, breastfeeding or intends&#xD;
             to become pregnant&#xD;
&#xD;
          -  Participation in any drug study within 30 days prior to dosing&#xD;
&#xD;
          -  Any other ineligible condition at the direction of the investigator that would be&#xD;
             ineligible to participate the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chul-Woo Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>222 Banpo-daero, Seocho-gu, Seoul, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seok Joon Shin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>56 Dongsuro, Pupyung-Gu, Incheon, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ki Young Na, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>82 Gumi-ro, 173 Beon-gil, Bundnag-gu, Seongnam-si, Gyeonggi-do, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ho cheol Song, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>327 sosaro, onemi-Gu, bucheon, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyeong cheoon Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>211 Eonju-ro, Gangnam-gu, Seoul, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Sun Kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>123 Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eun Young Seong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>176 Gudeok-ro, Seo-gu, Busan, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yong-Lim Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>130 Dongdeok-ro, Jung-gu, Dae-gu, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sangho Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>892 Dongnam-ro, Gangdong-gu, Seoul, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byung Chul Shin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>365 Pilmun-daero, Dong-gu, Gwangju Metropolitan City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Su-Hyun Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>102 Heukseok-ro, Dongjak-gu, Seoul, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyung Wook Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>93 Jungbu-daero, Paldal-gu, Suwon, Gyeonggi-do, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Won Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>20 Geonjiro Deokjin-gu, Jeonju-si, Jeollabuk-do, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young-il Jo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>4-12 Hwayang-dong, Gwangjin-gu, Seoul, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sug Kyun Shin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>100 Ilsan-ro, Ilsan-donggu, Goyang-si, Gyeonggi-do, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bucheon St. Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bundang Seoul National University College of Medicine</name>
      <address>
        <city>Gumi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Incheon St.Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2014</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

